Environmental Health Perspectives by Sand, Salomon et al.
Perspectives | Correspondence
A 264 volume 120 | number 7 | July 2012 • Environmental Health Perspectives
Approaches to Human Health 
Risk Assessment Based on the 
Signal‑To‑Noise Crossover Dose
http://dx.doi.org/10.1289/ehp.1205212
We acknowledge the effort of Sand et al. 
(2011) in striving to develop a transparent, 
objective procedure for point of departure 
(POD) estimation, as encouraged by scien­
tific review groups (National Research 
Council 2009). Although additional charac­
teri za tion of the statistical properties of 
the signal­to­noise crossover dose (SNCD) 
may be warranted, the goal of Sand 
et al. (2011) appears consistent with the 
intent of the POD to charac terize “the 
beginning of extrapolation to lower doses” 
[U.S. Environmental Protection Agency 
(EPA) 2005]. In this letter we respond to 
the authors’ illustration of their approach 
using cancer bio assay data to develop 
reference doses (RfDs) that target a 1/1,000 
risk through linear extrapolation from the 
POD by highlighting opportunities to 
augment their statistically based approach 
with biological considerations. 
For most carcinogens, the U.S. EPA 
develops cancer potency estimates as follows 
(U.S. EPA 2005). A POD associated with a 
benchmark response level (BMR) is derived 
and converted to human­equivalent units 
(incorporating information about cross­
species dose scaling). The BMR is then 
divided by the human­equivalent POD 
to obtain a potency estimate, under the 
assumption that risks extrapolate linearly 
with doses below the BMR. For Sand et al. 
(2011), the upper­bound extra risk estimate 
(UERSNCD) is the BMR associated with 
the SNCD, but we recom mend expressing 
SNCDs in human equivalents before 
deriving potency estimates. 
For nonlinear extrapolation resulting 
in a RfD (which the U.S. EPA uses for 
non cancer effects and carcinogens with a 
threshold mode of action), Sand et al. 
(2011) chose to linearly extrapolate to 
a 1/1,000 risk in the test animal, which 
they considered analogous to applying a 
100­fold uncertainty factor to a BMDL10 
(lower bound on the benchmark dose 
corresponding to 10% extra risk). Several 
aspects of this proposal merit further 
considera tion. First, margins of exposure 
much larger than 100­fold would be typical 
for cancer. Furthermore, whereas linear 
extrapo la tion involves extrapolation in the 
same population to a smaller level of effect, 
the standard uncertainty factor approach 
involves extrapolation across populations 
at a fixed level of effect. The alternative 
we propose separately accounts for these 
biologically unrelated processes. 
Motivating our proposal is the need 
highlighted by Sand et al. (2011) to clearly 
separate statistical factors supporting the 
level of effect associated with the POD 
while also fully incorporating biologi­
cal considerations. We propose specify­
ing “target” effect levels (TELs) associated 
with different end points based on biologi­
cal considerations, independent of data set. 
The TELs could then be compared with 
the lowest practical BMR for a given data 
set—the UERSNCD used by Sand et al. 
The UERSNCD/TEL ratio is a diagnostic 
of the extent of extrapolation to the TEL. 
If UERSNCD ≤ TEL, then the BMD at the 
TEL does not involve extrapo la tion and can 
serve as the POD. For a UERSNCD > TEL, 
the greater the ratio, the greater the uncer­
tainty in the BMD at the TEL from extrapo­
la tion below the SNCD. In this case, the 
SNCD could serve as the POD, and the gap 
between the UERSNCD and the TEL could 
be bridged by an additional factor (analo­
gous to the LOAEL­to­NOAEL factor) 
or linear extrapolation. Then, inter species, 
intra species, and any other adjustments for 
deriving RfDs would be applied as usual. 
Thus, this approach separately takes into 
account biological considerations related to 
the severity of the end point (via the TEL), 
statistical considerations related to the study 
data (via the UERSNCD), and adjustments 
from the test species to sensitive humans 
(via uncertainty factors or chemical­specific 
adjustments). 
In sum, the work of Sand et al. (2011)
advances the development of approaches for 
providing a transparent, objective method 
to demark where “extrapolation begins.” 
However, for human health risk assessment, 
we propose augmenting statistically based 
approaches so that inter­ and intra species 
adjustments and biological considerations 
relating to the end points are explicitly 
addressed. Although consensus on specify­
ing TELs may be challenging, particularly 
for precursor or toxico genomic end points, 
clearly separating biological and statistical 
considerations will enhance the transparency 
and consistency of chemical assessments.
The views in this article are those of the 
authors and do not necessarily reflect the views or 
policies of the U.S. EPA.
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We appreciate the opportunities highlighted 
by Chiu et al. to augment the concept of the 
signal­to­noise crossover dose (SNCD) (Sand 
et al. 2011) with biological consideration. In 
similarity to our interpretation of the SNCD 
concept, Chiu et al. note that our approach 
provides a transparent and objective method 
to demark where extrapolation begins and 
that it appears consistent with the intent 
of the point of departure (POD) to char­
acterize “the beginning of extrapolation to 
lower doses” (U.S. Environmental Protection 
Agency 2005). 
In our article (Sand et al. 2011), we 
compared the SNCD with traditional PODs 
used in risk assessment [i.e., the benchmark 
dose (BMD) and the no observed adverse effect 
level (NOAEL)]. In addition, we compared 
human exposure guidelines [generally referred 
to as reference doses (RfDs) in our article] 
resulting from using the SNCD, the BMD, 
and the NOAEL as PODs. The SNCD­based 
exposure guideline was derived by linear 
extrapolation from the upper bound on extra 
risk at the SNCD (UERSNCD) down to a target 
risk of 1/1,000. When considering new risk 
assessment strategies, an initial step is to address 
how they compare against more traditional 
approaches. The specific settings we used in 
the derivation of the SNCD­based exposure 
guideline were selected primarily as a result of 
such considerations; that is, using these settings, 
the SNCD concept can be compared to more 
standard BMD and NOAEL approaches at 
the level of the human exposure guideline in a 
calibrated manner, providing a starting point 
for further discussion. 
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In our article (Sand et al. 2011) we 
suggested that further development of the 
SNCD concept could involve the use of 
alterna tive target risks (e.g., based on public 
health con siderations, as well as alternative 
low­dose extrapolation models), and we also 
pointed out that animal­to­human extrapola­
tion may be regarded as a separate step after 
the SNCD­based POD has been established. 
This appears to be in line with the develop­
ments proposed by Chiu et al. in their letter. 
Generally speaking, they suggest an approach 
that separately takes into account biological 
considerations related to the severity of the 
end point via the target effect level (TEL), 
statistical considerations related to the study 
data via the UERSNCD, and adjustments from 
the test species to sensitive humans, after 
the POD associated with the TEL has been 
derived, via uncertainty factors or chemical­
specific adjustments.
Chiu et al. suggests in more detail that if 
UERSNCD < TEL, the POD corresponding 
to that TEL can be derived directly, whereas 
the case UERSNCD > TEL indicates that 
low­dose extrapolation from the SNCD is 
required to reach the dose associated with 
the TEL (where UERSNCD/TEL measures 
the extent of extrapolation). In principal, 
this appears reasonable provided that the 
SNCD concept is generalized to any type 
of response data (i.e., not only cancer, 
but continuous or quantal end points in 
general). The SNCD may then represent 
a starting point for low­dose extrapolation 
when the upper bound on risk (extra risk) 
or continuous effect (e.g., relative effect) 
at the SNCD is higher than what is 
considered acceptable from a biological or 
risk management point of view; although 
TELs should ideally be fully biologically 
based, a certain level of policy is likely to 
be involved, including use of default values. 
It remains to be seen in practice how the 
SNCD compares with PODs corresponding 
to default benchmark response (BMR) 
levels, TELs, or other such measures, for 
various types of response data. 
We are in the process of extending the 
comparison of different PODs performed 
in our previous study (Sand et al. 2011) 
to the case of high  throughput screening 
data. Accounting for the severity of effect for 
such data is a major challenge, for example, 
using a TEL/BMR concept or perhaps 
requiring development of multivariate/
multidimensional extensions thereof. We 
agree that separating biological and statistical 
considerations will enhance the transparency 
and consistency of chemical assessments.
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